165 related articles for article (PubMed ID: 8166126)
21. The evaluation of the data collection process for a multicenter, population-based, case-control design.
Wingo PA; Ory HW; Layde PM; Lee NC
Am J Epidemiol; 1988 Jul; 128(1):206-17. PubMed ID: 3381827
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for epithelial ovarian tumours of borderline malignancy.
Parazzini F; Restelli C; La Vecchia C; Negri E; Chiari S; Maggi R; Mangioni C
Int J Epidemiol; 1991 Dec; 20(4):871-7. PubMed ID: 1800425
[TBL] [Abstract][Full Text] [Related]
23. Oral contraceptives and ovarian cancer.
La Vecchia C; Franceschi S
Eur J Cancer Prev; 1999 Aug; 8(4):297-304. PubMed ID: 10493304
[TBL] [Abstract][Full Text] [Related]
24. The reduction in risk of ovarian cancer associated with oral-contraceptive use.
Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development
N Engl J Med; 1987 Mar; 316(11):650-5. PubMed ID: 3821795
[TBL] [Abstract][Full Text] [Related]
25. An epidemiologic study of ovarian cancer. Part 11: Oral contraceptive use and menstrual events.
Badawy YA; Bayoumi DM
J Egypt Public Health Assoc; 1992; 67(5-6):579-91. PubMed ID: 1294683
[TBL] [Abstract][Full Text] [Related]
26. Oral contraceptive use and the risk of ovarian cancer. The Centers for Disease Control Cancer and Steroid Hormone Study.
JAMA; 1983 Mar; 249(12):1596-9. PubMed ID: 6338264
[TBL] [Abstract][Full Text] [Related]
27. Factors affecting the association of oral contraceptives and ovarian cancer.
Cramer DW; Hutchison GB; Welch WR; Scully RE; Knapp RC
N Engl J Med; 1982 Oct; 307(17):1047-51. PubMed ID: 7121514
[TBL] [Abstract][Full Text] [Related]
28. Oral contraceptives and life expectancy.
Fortney JA; Harper JM; Potts M
Stud Fam Plann; 1986; 17(3):117-25. PubMed ID: 3523849
[TBL] [Abstract][Full Text] [Related]
29. "Incessant ovulation" and ovarian cancer.
Casagrande JT; Louie EW; Pike MC; Roy S; Ross RK; Henderson BE
Lancet; 1979 Jul; 2(8135):170-3. PubMed ID: 89281
[TBL] [Abstract][Full Text] [Related]
30. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis.
Modugno F; Ness RB; Allen GO; Schildkraut JM; Davis FG; Goodman MT
Am J Obstet Gynecol; 2004 Sep; 191(3):733-40. PubMed ID: 15467532
[TBL] [Abstract][Full Text] [Related]
31. Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer.
Greer JB; Modugno F; Allen GO; Ness RB
Obstet Gynecol; 2005 Apr; 105(4):731-40. PubMed ID: 15802398
[TBL] [Abstract][Full Text] [Related]
32. Oral contraceptive use and invasive cervical cancer.
Parazzini F; la Vecchia C; Negri E; Maggi R
Int J Epidemiol; 1990 Jun; 19(2):259-63. PubMed ID: 2376433
[TBL] [Abstract][Full Text] [Related]
33. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study.
Iversen L; Fielding S; Lidegaard Ø; Mørch LS; Skovlund CW; Hannaford PC
BMJ; 2018 Sep; 362():k3609. PubMed ID: 30257920
[TBL] [Abstract][Full Text] [Related]
34. Risk factors for epithelial ovarian cancer in Beijing, China.
Chen Y; Wu PC; Lang JH; Ge WJ; Hartge P; Brinton LA
Int J Epidemiol; 1992 Feb; 21(1):23-9. PubMed ID: 1544753
[TBL] [Abstract][Full Text] [Related]
35. Oral contraceptive use and the risk of epithelial ovarian cancer.
La Vecchia C; Franceschi S; Decarli A
Br J Cancer; 1984 Jul; 50(1):31-4. PubMed ID: 6743513
[TBL] [Abstract][Full Text] [Related]
36. Oral contraceptives as related to cancer and benign lesions of the breast.
Fasal E; Paffenbarger RS
J Natl Cancer Inst; 1975 Oct; 55(4):767-73. PubMed ID: 1185801
[TBL] [Abstract][Full Text] [Related]
37. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions.
Ness RB; Grisso JA; Klapper J; Schlesselman JJ; Silberzweig S; Vergona R; Morgan M; Wheeler JE
Am J Epidemiol; 2000 Aug; 152(3):233-41. PubMed ID: 10933270
[TBL] [Abstract][Full Text] [Related]
38. Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancer.
Faber MT; Jensen A; Frederiksen K; Glud E; Høgdall E; Høgdall C; Blaakaer J; Kjaer SK
Cancer Causes Control; 2013 Dec; 24(12):2197-206. PubMed ID: 24077761
[TBL] [Abstract][Full Text] [Related]
39. Oral contraceptives and breast cancer.
Brinton LA; Hoover R; Szklo M; Fraumeni JF
Int J Epidemiol; 1982 Dec; 11(4):316-22. PubMed ID: 7152784
[TBL] [Abstract][Full Text] [Related]
40. Family history of cancer, oral contraceptive use, and ovarian cancer risk.
Walker GR; Schlesselman JJ; Ness RB
Am J Obstet Gynecol; 2002 Jan; 186(1):8-14. PubMed ID: 11810077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
